TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28639937
Drug: IV methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV methylprednisolone plus 2 g/kg of IVIG in divided doses within 5 days of the first commencement of steroid therapy
Study: 26315981
Drug: Extended-release guanfacine
Normalized name: guanfacine Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release guanfacine (N=30)
Study: 21289620
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose Sativex (5.4 mg THC, 5.0 mg CBD)
Study: 21289620
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose Sativex (16.2 mg THC, 15.0 mg CBD)
Study: 22027622
Drug: Erythropoietin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythropoietin (500 IU/kg) and iron sucrose (200 mg)
Study: 19429471
Drug: Mirtazapine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (30 mg oral dose)
Study: 9278211
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 mg daily for 21 days) + Warfarin (25 mg single dose)
Study: 8338265
Drug: 1% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1% dextrose in lactated Ringer's solution (RLG1)
Study: 8338265
Drug: 0.9% dextrose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% dextrose in lactated Ringer's solution (B66)
Study: 3495027
Drug: TMP‐SMZ (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMZ (50 mg/kg daily)
Study: 3495027
Drug: TMP‐SMZ (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: TMP‐SMZ (normal G‐6‐PD)
Study: 3495027
Drug: Vancomycin (normal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin (normal G‐6‐PD)
Study: 29052439
Drug: Dual peroxisome
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual peroxisome proliferator-activated receptor agonist aleglitazar
Study: 27160738
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment (motor learning-based treatment)
Study: 27160738
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (treatment if needed after the study)
Study: 22951500
Drug: Etidronate (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etidronate (400 mg/d orally for 14 days quarterly)
Study: 22105813
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg/d)
Study: 22951500
Drug: Calcium plus
Normalized name: O Calcium Plus D
DrugBank: Cupric oxide (DB11134)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium plus Vitamin D3 (1000 mg/d calcium plus 800 IU/d vitamin D3)
Study: 16537378
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral N-acetylcysteine (0.6 to 1.0 g three times daily, for 4 weeks)
Study: 16537378
Drug: High-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose oral N-acetylcysteine
Study: 11130773
Drug: Losartan (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan (100 mg/day for 8 days)
Study: 9058689
Drug: Inhaled heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled heparin (15,000 units USP/ml, 4 ml)
Study: 7862817
Drug: Intravenous benztropine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous benztropine (2 mg)
Study: 4877600
Drug: Propranolol (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (1 mg)
Study: 3732769
Drug: Chenodiol (chenodeoxycholate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol (chenodeoxycholate), 750 mg/day
Study: 3732769
Drug: Chenodiol (chenodeoxycholate),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chenodiol (chenodeoxycholate), 375 mg/day
Study: 29779170
Drug: Oligofructose (8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oligofructose (8 g/day for 12 weeks followed by 16 g/day for 24 weeks)
Study: 23258641
Drug: Transdermal electromotive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal electromotive administration of verapamil (10 mg) and dexamethasone (4 mg)
Study: 23258641
Drug: Intra-lesional injection
Normalized name: scabies lesion lysate (human)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-lesional injection of verapamil (10 mg) and dexamethasone (4 mg)
Study: 23258641
Drug: Transdermal electromotive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal electromotive administration of verapamil and dexamethasone
Study: 21291509
Drug: Teams that
Approvals — FDA: no, EMA: no, PMDA: no
Description: Teams that administered magnesium sulfate within the allocated time (10 minutes).
Study: 15050862
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg and 2 mg on 2 successive days)
Study: 9489052
Drug: Methadone doses
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methadone doses
Study: 27071477
Drug: Experimental Group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental Group (EG) - Four weeks of APA-focused training involving catching a medicine ball while standing
Study: 24694794
Drug: AST-120 (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: AST-120 (2 g 3 times daily for 8 weeks)
Study: 22348845
Drug: 1.5 ml
Normalized name: Humulin 70/30 1.5 ML Pen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 ml 0.75% ropivacaine to the tonsil lodge
Study: 22348845
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg i.v. tramadol
Study: 21054850
Drug: Selective V(2)R-antagonist
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selective V(2)R-antagonist (1 μg/kg per hour)
Study: 21054850
Drug: AVP (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVP (0.05 μg/kg per hour)
Study: 10686834
Drug: Presurgical oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presurgical oral health (OHSQ)
Study: 8363468
Drug: Multivitamin/mineral supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivitamin/mineral supplement
Study: 31917319
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplement
Study: 10709535
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (injection given in a slow manner without the distraction technique)
Study: 1683217
Drug: 400 mg/day
Normalized name: ribociclib succinate 400 mg/day (200 mg x 2) ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg/day oral celiprolol
Study: 1683217
Drug: 120 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 120 mg/day oral nicardipine
Study: 31198048
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity coaching program (18 months, monthly follow-up by physiotherapist)
Study: 23720981
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Zinc sulfate supplementation (50 mg per meal, three times a day)
Study: 21083540
Drug: Ketorolac (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac (0.5 mg/kg bolus, 83.3 microg/kg/h infusion for 48 h)
Study: 21083540
Drug: Fentanyl (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (1 microg/kg bolus, 0.17 microg/kg/h infusion for 48 h)
Study: 15534261
Drug: Antioxidants (vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; beta carotene, 15 mg)
Study: 15534261
Drug: Zinc and
Normalized name: Zinc and/or zinc compound
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc and copper (zinc, 80 mg; cupric oxide, 2 mg)
Study: 31606455
Drug: Obeticholic acid
Normalized name: Obeticholic acid
DrugBank: Obeticholic acid (DB05990)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Obeticholic acid (OCA) 5 to 10 mg daily
Study: 21735193
Drug: Acetic acid-moistened
Normalized name: Acetic Acid
DrugBank: Acetic acid (DB03166)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetic acid-moistened misoprostol tablets
Study: 21735193
Drug: Dry misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dry misoprostol tablets
Study: 15136504
Drug: Pravastatin treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pravastatin treatment (MTP-493GG genotype)
Study: 29570475
Drug: Control (high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (high-dose corticosteroids)
Study: 23299763
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid)
Study: 23299763
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with high basal free radicals
Study: 23299763
Drug: Acute oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute oral antioxidant cocktail (AOC, vitamins C and E, and alpha‐lipoic acid) in patients with low basal free radicals
Study: 12639160
Drug: Ginkgo biloba
Normalized name: Ginkgo Biloba
DrugBank: Ginkgo biloba (DB01381)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginkgo biloba 120 mg
Study: 11043871
Drug: Additional-exercise treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional-exercise treatment group (AT group)
Study: 11043871
Drug: Regular treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular treatment group (RT group)
Study: 9124404
Drug: Insulin-like growth
Normalized name: Insulin-like growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin-like growth factor (IGF-I) 100 microg/kg subcutaneously every 12 h for 6 doses
Study: 9702254
Drug: Antiviral and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral and immunostimulative treatment with Romanian specific products
Study: 27419471
Drug: fractional laser
Normalized name: LIVER FRACTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: fractional laser plus topical lidocaine cream (Group LaserAnes)
Study: 27419471
Drug: sham irradiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: sham irradiation plus topical anesthesia (Group Anes)
Study: 18006189
Drug: Ondansetron (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ondansetron (0.15 mg/kg orally dissolving tablet)
Study: 16356219
Drug: Post-operative goal-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-operative goal-directed therapy (GDT)
Study: 1675329
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy home service (6-week comprehensive programme)
Study: 1675329
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no treatment for 6 weeks)
Study: 29411520
Drug: 0.02% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.02% triamcinolone acetonide cream
Study: 26932305
Drug: Vildagliptin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin FDC tablets (50/250 mg)
Study: 26932305
Drug: Vildagliptin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin FDC tablets (50/500 mg)
Study: 26932305
Drug: Vildagliptin/metformin FDC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vildagliptin/metformin FDC tablets (50/500 mg) after meals
Study: 26932305
Drug: Metformin under
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin under fed condition
Study: 24699052
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mixed tocotrienols twice a day for 2 years
Study: 17488783
Drug: Psychodynamic interpersonal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychodynamic interpersonal therapy
Study: 19829284
Drug: 5-HT4 agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-HT4 agonists
Study: 16084157
Drug: eptifibatide +
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eptifibatide + tenecteplase (0.25 mg/kg intravenous bolus)
Study: 12373040
Drug: Hormone replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone replacement therapy (HRT) consisting of transdermal application of continuous 17beta‐estradiol with cyclic medroxyprogesterone acetate (MPA) tablets for 14 days every 3rd month
Study: 10197835
Drug: Pindolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5 mg 3 times daily) for 10 days
Study: 10197835
Drug: Placebo (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (3 times daily) for 10 days
Study: 2179850
Drug: Intramuscular vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular vitamin E (dl-alpha-tocopherol) on days 1, 2, 4, and 6 of life
Study: 2179850
Drug: Intramuscular placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular placebo injections on the same schedule
Study: 2179850
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E treatment in survivors
Study: 30281813
Drug: Tooth brushing
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth brushing once daily
Study: 30281813
Drug: Tooth brushing
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth brushing twice daily
Study: 30281813
Drug: Tooth brushing
Normalized name: Sus scrofa tooth preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tooth brushing three times daily
Study: 24219618
Drug: High-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paracetamol (40 mg/kg body weight, max 2000 mg)
Study: 24219618
Drug: High-dose paracetamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose paracetamol
Study: 22948036
Drug: UDCA (13‐15
Approvals — FDA: no, EMA: no, PMDA: no
Description: UDCA (13‐15 mg/kg/day for 4 weeks)
Study: 20739431
Drug: Bortezomib after
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib after high-dose melphalan
Study: 20739431
Drug: Bortezomib before
Normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bortezomib before high-dose melphalan
Study: 18188757
Drug: Nicotine replacement
Normalized name: Nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nicotine replacement therapy overnight
Study: 18188757
Drug: Treatments that
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments that improve sleep quality
Study: 9196769
Drug: Mefloquine 250
Normalized name: mefloquine 250 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mefloquine 250 mg weekly
Study: 1330396
Drug: Treatment A
Normalized name: Nix Ultra Lice Treatment And Prevention Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment A (solution, fasted)
Study: 1330396
Drug: Treatment B
Normalized name: PanOxyl Acne Treatment Bar
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment B (capsule with food)
Study: 1330396
Drug: Treatment C
Normalized name: Acne Treatment Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment C (capsule without food)
Study: 1330396
Drug: Equiactive metabolite
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment A
Study: 1330396
Drug: Equiactive metabolite
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment B
Study: 1330396
Drug: Equiactive metabolite
Normalized name: Terfenadine acid metabolite
DrugBank: Fexofenadine (DB00950)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Equiactive metabolite 25-O-deacetyl-rifabutin for Treatment C
Study: 31342474
Drug: 19 G
Normalized name: Sharps Collector 19 Gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 G Franseen-tip core biopsy needle (FNB)
Study: 31342474
Drug: 19 G
Normalized name: Sharps Collector 19 Gal
Approvals — FDA: no, EMA: no, PMDA: no
Description: 19 G aspiration needle (FNA)
Study: 29852863
Drug: Omega-3 (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omega-3 (300 mg daily)
Study: 24898101
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral antibiotic switch (group A)
Study: 24898101
Drug: Conventional intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional intravenous antibiotics (group B)
Study: 22940436
Drug: Electrically Heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K6 cigarette (5mg tar, 0.3mg nicotine, and 0.6 mg CO)
Study: 22940436
Drug: Electrically Heated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrically Heated Cigarette Smoking System (EHCSS) - EHCSS-K3 cigarette (3mg tar, 0.2mg nicotine, and 0.6 mg CO)
Study: 22940437
Drug: Marlboro cigarettes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Marlboro cigarettes (6 mg tar, 0.5mg nicotine, and 7.0mg CO)
Study: 18294729
Drug: Supplemental oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplemental oxygen (3 L/minute)
Study: 11798671
Drug: Captopril (12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (12.5mg three times daily)
Study: 1746790
Drug: Ranitidine elixir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine elixir 3 mg/kg via nasogastric tube every 12 hours
Study: 1746790
Drug: Intravenous (IV)
Normalized name: intravenous (IV) infusion pump
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (IV) ranitidine 1 mg/kg every 8 hours
Study: 6700849
Drug: Single 2-g
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single 2-g preoperative dose of cefoxitin
Study: 6700849
Drug: Three 2-g
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Three 2-g doses of cefoxitin over 12 hours
Study: 29948596
Drug: Essential oil
Normalized name: Essential oil
DrugBank: Rosemary oil (DB14689)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Essential oil treatment applied by self-massage on the suprapubic and sacral region once a day for 4 weeks.
Study: 30275687
Drug: 24-week multicomponent
Normalized name: lacosamide
DrugBank: Lacosamide (DB06218)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 24-week multicomponent intervention (group exercise, nutritional supplementation, depression management, deprescribing medications, home hazard reduction)
Study: 21343348
Drug: Etamicastat (2,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat (2, 10, 20, 50, 100, 200, 400, 600, 900, or 1200 mg)
Study: 21343348
Drug: Etamicastat (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etamicastat (100 mg and above)
Study: 20339359
Drug: Weight reduction
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight reduction (BMI reduction by 1 SDS, n = 51; and 2 SDS, n = 21) under conservative treatment for 18 months.
Study: 1744867
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg timolol orally
Study: 30045259
Drug: Melatonin (ML)
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Melatonin (ML)
Study: 26162825
Drug: EVICEL™ applied
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVICEL™ applied during surgery (5 ml)
Study: 26162825
Drug: Electrocoagulation (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electrocoagulation (standard treatment)
Study: 20673353
Drug: Adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant chemotherapy (28 day cycles of cyclophosphamide, methotrexate and 5‐fluorouracil)
Study: 20673353
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no specific treatment mentioned)
Study: 18486740
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 8 weeks (for partial responders)
Study: 18486740
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg every 12 weeks (for partial responders)
Study: 18486740
Drug: Ustekinumab 45
Normalized name: USTEKINUMAB 45MG/0.5ML INJ 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 45 mg (for partial responders)
Study: 12531444
Drug: Ceftriaxone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone (1 g IV at induction of anesthesia)
Study: 12531444
Drug: Cefotaxime (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (1 g IV at induction of anesthesia)
Study: 11064186
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg sublingual buprenorphine + 0 mg naloxone
Study: 11064186
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg sublingual buprenorphine + 4 mg naloxone
Study: 11064186
Drug: 8 mg
Normalized name: alloin 8 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 mg sublingual buprenorphine + 8 mg naloxone
Study: 11064186
Drug: Intravenous buprenorphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous buprenorphine + naloxone
Study: 11064186
Drug: Buprenorphine bioavailability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buprenorphine bioavailability
Study: 11064186
Drug: Naloxone bioavailability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone bioavailability
Study: 1788149
Drug: DDAVP (0.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: DDAVP (0.6 ml intranasal dose, 60 micrograms)
Study: 7101088
Drug: Cefonicid (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefonicid (1 g, intramuscularly)
Study: 7101088
Drug: Procaine penicillin
Normalized name: procaine penicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Procaine penicillin G (4.8 x 10^6 units) plus probenecid (1.0 g)
Study: 30209152
Drug: Oral TN-TC11M
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral TN-TC11M (THC 2.5mg/CBD 2.5mg) capsules
Study: 27871549
Drug: Epidural chloroprocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural chloroprocaine 1.2% mixed with 0.4μg/mL fentanyl
Study: 18795916
Drug: V. filiformis
Approvals — FDA: no, EMA: no, PMDA: no
Description: V. filiformis cream 5%
Study: 16176175
Drug: zidovudine+lamivudine treatment
Normalized name: lamivudine / zidovudine
Approvals — FDA: no, EMA: no, PMDA: no
Description: zidovudine+lamivudine treatment
Study: 16176175
Drug: didanosine+stavudine treatment
Normalized name: Stavudine
DrugBank: Stavudine (DB00649)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: didanosine+stavudine treatment
Study: 15184979
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 mg once daily for 6 weeks)